Progeria natural history, complications and prognosis: Difference between revisions
| Line 38: | Line 38: | ||
*Prognosis is generally poor, in patients with Hutchinson-Gilford progeria syndrome (HGPS).<ref name="pmid24795390">{{cite journal| author=Gordon LB, Massaro J, D'Agostino RB, Campbell SE, Brazier J, Brown WT et al.| title=Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. | journal=Circulation | year= 2014 | volume= 130 | issue= 1 | pages= 27-34 | pmid=24795390 | doi=10.1161/CIRCULATIONAHA.113.008285 | pmc=4082404 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24795390 }}</ref> | *Prognosis is generally poor, in patients with Hutchinson-Gilford progeria syndrome (HGPS).<ref name="pmid24795390">{{cite journal| author=Gordon LB, Massaro J, D'Agostino RB, Campbell SE, Brazier J, Brown WT et al.| title=Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. | journal=Circulation | year= 2014 | volume= 130 | issue= 1 | pages= 27-34 | pmid=24795390 | doi=10.1161/CIRCULATIONAHA.113.008285 | pmc=4082404 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24795390 }}</ref> | ||
*The presence of progressive atherosclerosis is associated with a particularly poor prognosis among patients with Hutchinson-Gilford progeria syndrome (HGPS). | *The presence of progressive atherosclerosis is associated with a particularly poor prognosis among patients with Hutchinson-Gilford progeria syndrome (HGPS). | ||
*The average lifespan of patients with Hutchinson-Gilford progeria syndrome (HGPS) is about 15 years. | |||
==References== | ==References== | ||
Revision as of 17:00, 27 July 2019
|
Progeria Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Progeria natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Progeria natural history, complications and prognosis |
|
FDA on Progeria natural history, complications and prognosis |
|
CDC on Progeria natural history, complications and prognosis |
|
Progeria natural history, complications and prognosis in the news |
|
Blogs on Progeria natural history, complications and prognosis |
|
Risk calculators and risk factors for Progeria natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of Hutchinson-Gilford progeria syndrome (HGPS) usually develop in the first decade of life, and start with symptoms as follows:[1][2]
- Failure to thrive
- Loss of subcutaneous fat
- Poor weight gain
- Weight increase of only 0.44 kg/year
- Short stature
- Decreased linear weight gain
- Alopecia
Complications
- Common complications of Hutchinson-Gilford progeria syndrome (HGPS) include:[3][4]
- Progressive atherosclerosis
- Myocardial infarction
- Transient ischemic attack (TIA)
- Stroke
- Exposure keratopathy
- Conductive hearing loss
Prognosis
- Prognosis is generally poor, in patients with Hutchinson-Gilford progeria syndrome (HGPS).[5]
- The presence of progressive atherosclerosis is associated with a particularly poor prognosis among patients with Hutchinson-Gilford progeria syndrome (HGPS).
- The average lifespan of patients with Hutchinson-Gilford progeria syndrome (HGPS) is about 15 years.
References
- ↑ Gordon LB, McCarten KM, Giobbie-Hurder A, Machan JT, Campbell SE, Berns SD; et al. (2007). "Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development". Pediatrics. 120 (4): 824–33. doi:10.1542/peds.2007-1357. PMID 17908770.
- ↑ Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB; et al. (2008). "Phenotype and course of Hutchinson-Gilford progeria syndrome". N Engl J Med. 358 (6): 592–604. doi:10.1056/NEJMoa0706898. PMC 2940940. PMID 18256394.
- ↑ Ullrich NJ, Gordon LB (2015). "Hutchinson-Gilford progeria syndrome". Handb Clin Neurol. 132: 249–64. doi:10.1016/B978-0-444-62702-5.00018-4. PMID 26564085.
- ↑ Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K; et al. (1993). "GeneReviews®". PMID 20301300.
- ↑ Gordon LB, Massaro J, D'Agostino RB, Campbell SE, Brazier J, Brown WT; et al. (2014). "Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome". Circulation. 130 (1): 27–34. doi:10.1161/CIRCULATIONAHA.113.008285. PMC 4082404. PMID 24795390.